Frede, Julia http://orcid.org/0000-0002-4380-9673
Anand, Praveen http://orcid.org/0000-0002-2478-7042
Sotudeh, Noori http://orcid.org/0000-0002-1683-7273
Pinto, Ricardo A. http://orcid.org/0000-0002-9175-1357
Nair, Monica S.
Stuart, Hannah
Yee, Andrew J.
Vijaykumar, Tushara
Waldschmidt, Johannes M.
Potdar, Sayalee
Kloeber, Jake A. http://orcid.org/0000-0002-6646-564X
Kokkalis, Antonis http://orcid.org/0000-0001-7779-0600
Dimitrova, Valeriya
Mann, Mason
Laubach, Jacob P.
Richardson, Paul G.
Anderson, Kenneth C. http://orcid.org/0000-0002-6418-0886
Raje, Noopur S.
Knoechel, Birgit http://orcid.org/0000-0002-8040-0535
Lohr, Jens G. http://orcid.org/0000-0003-3486-2445
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA191026)
V Foundation for Cancer Research
Anna Fuller Fund
Article History
Received: 11 November 2020
Accepted: 31 August 2021
First Online: 21 October 2021
Competing interests
: A.J.Y. has a consulting role for Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Sanofi and Takeda. The remaining authors declare no competing interests.